Group 1 - The core point of the news is that E Fund Management Co., Ltd. has increased its stake in Tiger Med (03347.HK) by purchasing 66,200 shares at an average price of HKD 53.8841 per share, resulting in a total investment of approximately HKD 3.5671 million [1] - After the purchase, E Fund's total shareholding in Tiger Med reached 14.8183 million shares, increasing its ownership percentage from 11.98% to 12.04% [1]

Group 1 - The core focus of the company is on addressing significant unmet clinical needs and empowering innovative enterprises for pharmaceutical innovation [1] - The event "Shenzhen Stock Exchange · Innovation Forum" for the biopharmaceutical industry was held in Hangzhou on August 5 [1] - The general manager of the company, Cao Xiaochun, emphasized the commitment to supporting the growth of innovative companies [1]

Group 1 - The core viewpoint of the news is that Tiger Medical (300347) has shown a decline in revenue and net profit in its latest quarterly report, indicating potential challenges ahead for the company [1] - As of August 8, 2025, Tiger Medical's stock closed at 65.24 yuan, with a slight increase of 0.88% and a trading volume of 78500 lots, amounting to 507 million yuan [1] - The company's latest quarterly report shows total revenue of 1.564 billion yuan, a year-on-year decrease of 5.79%, and a net profit attributable to shareholders of 165 million yuan, down 29.61% year-on-year [1] Group 2 - The company's non-recurring net profit was reported at 102 million yuan, reflecting a significant year-on-year decrease of 66.23% [1] - The liquidity ratios indicate a current ratio of 1.622 and a quick ratio of 1.611, with a debt-to-asset ratio of 16.78% [1] - Tiger Medical has made investments in 55 companies and participated in 50 bidding projects, showcasing its active engagement in the market [2]

鉴于目前牛市市况，该行预料生物科技融资将有所改善，并相信泰格医药的投资收益将超过其核心业务 的临床服务费。此外，该行预料，泰格医药次季销售呈单位数同比正向增长，而去年首季至今年首季的 五个季度则录同比下跌;另料经营利润率按季有所改变。又预期由次季起，新订单持续按季改善。 智通财经APP获悉，里昂发布研报称，随着2025年上半年中国创新药市场情势好转，泰格医药(03347)股 价年初至今已上涨83%。该行维持对泰格医药2025至2027年的收入及经营溢利预测不变，料收入增长 7%至9%，净利润分别上调31%、30%及30%，目标价由34.2港元上调至62.6港元，维持"跑赢大市"评 级。 ...

鉴于目前牛市市况，该行预料生物科技融资将有所改善，并相信泰格医药的投资收益将超过其核心业务 的临床服务费。此外，该行预料，泰格医药次季销售呈单位数同比正向增长，而去年首季至今年首季的 五个季度则录同比下跌;另料经营利润率按季有所改变。又预期由次季起，新订单持续按季改善。 里昂发布研报称，随着2025年上半年中国创新药市场情势好转，泰格医药（300347）(03347)股价年初 至今已上涨83%。该行维持对泰格医药2025至2027年的收入及经营溢利预测不变，料收入增长7%至 9%，净利润分别上调31%、30%及30%，目标价由34.2港元上调至62.6港元，维持"跑赢大市"评级。 ...

Core Viewpoint - The report from Credit Lyonnais indicates that the Chinese innovative drug market is expected to improve in the first half of 2025, leading to an 83% increase in the stock price of Tigermed since the beginning of the year [1] Group 1: Market Conditions - The current bull market is anticipated to enhance biotechnology financing, suggesting a positive outlook for Tigermed's investment returns, which are expected to surpass its core clinical service fees [1] - The second quarter sales of Tigermed are projected to show single-digit year-on-year growth, contrasting with a year-on-year decline observed over the previous five quarters [1] Group 2: Financial Projections - Operating profit margins are expected to fluctuate quarterly, with new orders anticipated to improve on a quarterly basis starting from the second quarter [1] - The revenue and operating profit forecasts for Tigermed from 2025 to 2027 remain unchanged, with revenue growth expected between 7% and 9% [1] - Net profit estimates have been raised by 31%, 30%, and 30% for the respective years, with the target price adjusted from HKD 34.2 to HKD 62.6, maintaining an "outperform" rating [1]

资金流向方面，泰格医药当日主力资金净流出2383.75万元，近五日累计净流出1.22亿元。 风险提示：市场有风险，投资需谨慎。 来源:金融界 截至2025年8月6日15时，泰格医药股价报66.00元，较前一交易日下跌1.35%。当日开盘价为67.43元， 最高触及67.59元，最低下探65.69元，成交额达6.12亿元。 泰格医药属于医疗服务板块，是一家专注于为医药产品研发提供临床试验技术服务的公司，业务涵盖临 床研究、数据管理、统计分析等领域。 ...

致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 737,901,250 | RMB | | 1 RMB | | 737,901,250 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 737,901,250 | RMB | | 1 RMB | | 737,901,250 | | 2. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | -- ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 737,901,250 | RMB | | 1 RMB | | 737,901,250 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 737,901,250 | RMB | | 1 RMB | | 737,901,250 | | 2. 股份分類 | 普通股 | ...

天眼查商业履历信息显示，杭州泰格医药科技股份有限公司，成立于2004年，位于杭州市，是一家以从 事研究和试验发展为主的企业。企业注册资本86494.857万人民币，实缴资本86494.857万人民币。公司 法定代表人为曹晓春。 通过天眼查大数据分析，杭州泰格医药科技股份有限公司共对外投资了55家企业，参与招投标项目50 次，知识产权方面有商标信息38条，专利信息17条，此外企业还拥有行政许可45个。 来源：金融界 资金流向方面，今日主力资金净流入6821.03万元，占比成交额8.17%。其中，超大单净流入1366.92万 元、占成交额1.64%，大单净流入5454.11万元、占成交额6.53%，中单净流出流出1356.90万元、占成交 额1.63%，小单净流出5464.13万元、占成交额6.54%。 泰格医药最新一期业绩显示，截至2025一季报，公司营业总收入15.64亿元、同比减少5.79%，归属净利 润1.65亿元，同比减少29.61%，扣非净利润1.02亿元，同比减少66.23%，流动比率1.622、速动比率 1.611、资产负债率16.78%。 金融界消息 截至2025年8月5日收盘，泰格医药（300 ...